By InvitationNot Applicable

Long-Term Clinical Outcomes Of Subjects Enrolled In The RxSight Light Adjustable Lens (LAL) And Light Delivery Device (LDD) New Enrollment Study

United States500 participantsStarted 2025-11-13

Plain-language summary

This is an observational, follow up study of subjects previously enrolled in the "RxSight Light Adjustable Lens (LAL) and Light Delivery Device (LDD) New Enrollment Study". The primary objective of this study is to collect long-term safety and effectiveness data on RxSight LAL and Control IOL in subjects previously implanted in the "RxSight Light Adjustable Lens (LAL) and Light Delivery Device (LDD) New Enrollment Study".

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Subject and study eye with prior participation in the CSP-029 study. Exclusion Criteria: * Subjects with serious co-morbid conditions that in the judgment of the investigator makes inclusion in the study not in the best interest of the subject.

What they're measuring

Mean absolute manifest refraction spherical equivalent (|MRSE|) at the Long-Term follow up visit compared between the RxSight LAL and Control group

Timeframe: Up to 55 months

Mean manifest cylinder at the Long-Term follow up visit compared between the RxSight LAL and Control group

Timeframe: Up to 55 months

Trial details

NCT IDNCT07347379

SponsorRxSight, Inc.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2026-06

View on ClinicalTrials.gov More Aphakia Cataract trials